Cargando…

Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate

Imatinib has shown unprecendeted success in the treatment of chronic myeloid leukemia (CML). However, over few years there have been reports regarding the primary and secondary resistance to Imatinib dampening the overall outcome in CML patients. In this study we have tried to assess the effect of d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rajappa, Senthil, Mallavarapu, Krishna Mohan, Gundeti, Sadashivudu, Paul, Tara Roshni, Jacob, Rachel Thomas, Digumarti, Raghunadharao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902631/ https://www.ncbi.nlm.nih.gov/pubmed/24516316 http://dx.doi.org/10.4103/0971-5851.123750

Ejemplares similares

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Thiopurine methyltransferase polymorphisms in children with acute lymphoblastic leukemia
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Report of chronic myeloid leukemia in chronic phase from Dr. Senthil Rajappa, 2002-2009
por: Rajappa, Senthil, et al.
Publicado: (2013)

Metastatic adenocarcinoma in a young male, 12 years after treatment of primary non seminomatous germ cell tumor
por: Coca, Pragnya, et al.
Publicado: (2011)

Effectiveness of Three Prognostic Scoring Systems in Predicting the Response and Outcome in Pediatric Chronic Myeloid Leukemia Chronic Phase on Frontline Imatinib
por: Ganta, Ranga Raman, et al.
Publicado: (2017)

Epedimiologic, clinical profile and factors affecting the outcome in febrile neutropenia
por: Krishnamani, Kalpathi, et al.
Publicado: (2017)

Chronic myeloid leukemia: An Indian scenario
por: Digumarti, Raghunadharao
Publicado: (2016)

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013)

Primary pleuropulmonary synovial sarcoma: A report of two cases and review of literature
por: Kalpathi, Krishnamani, et al.
Publicado: (2013)

A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate
por: Kim, Min Sik, et al.
Publicado: (2010)

Prevalence and outcome of epidermal growth factor receptor mutations in non-squamous non-small cell lung cancer patients
por: Kota, Rajesh, et al.
Publicado: (2015)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
por: Vieira-Mion, Ana Lucia, et al.
Publicado: (2017)

Kaposi’s sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy
por: D’Addona, Matteo, et al.
Publicado: (2022)

The Role of Mutation Testing in Patients with Chronic Myeloid Leukemia in Chronic Phase after Imatinib Failure and Their Outcomes after Treatment Modification: Single-institutional Experience Over 13 Years
por: Chaitanya, Puligundla Krishna, et al.
Publicado: (2017)

Parasagittal hemangiopericytoma with late presentation of liver metastases: Case report and review of literature
por: Krishnamani, Kalpathi V., et al.
Publicado: (2013)

Clinical profile and outcome of adult Hodgkin lymphoma: Experience from a tertiary care institution
por: Maddi, Rahul Narayan, et al.
Publicado: (2015)

Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
por: Akay, Olga Meltem, et al.
Publicado: (2016)

Discontinuation of Imatinib Mesylate could Improve Renal Impairment in Chronic Myeloid Leukemia
por: Malkan, Umit Y., et al.
Publicado: (2018)

Lichenoid Drug Eruption after Low-Dose Imatinib Mesylate Treatment
por: Lee, Jae-Hyung, et al.
Publicado: (2013)

Multiple Eruptive Dermatofibromas Secondary to Imatinib Mesylate in a Patient with Chronic Myeloid Leukemia
por: Lira-Valero, Francisco J, et al.
Publicado: (2021)

Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
por: Go, Seong Woo, et al.
Publicado: (2013)

Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans
por: Aïssata, Tolo Diebkilé, et al.
Publicado: (2013)

Occurrence of Secondary Malignancies in Chronic Myeloid Leukemia During Therapy with Imatinib Mesylate-Single Institution Experience
por: Helbig, Grzegorz, et al.
Publicado: (2015)

Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML)
por: El Jurdi, Najla, et al.
Publicado: (2016)

Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced Gastrointestinal stromal tumors – a real-world multi-center study
por: Huang, Shaoqing, et al.
Publicado: (2023)

Multiplex Approach in Classification, Diagnosis, and Prognostication in Acute Myeloid Leukemia: An Experience from Tertiary Cancer Center in South India
por: Khera, Rachna, et al.
Publicado: (2017)

CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia
por: Halpern, Anna B., et al.
Publicado: (2018)

The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation
por: Conchon, Monika, et al.
Publicado: (2009)

Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?
por: Al-Dewik, Nader I., et al.
Publicado: (2016)

Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate
por: Batra, Jaskaran, et al.
Publicado: (2023)

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
por: Mita, Akiko, et al.
Publicado: (2018)

Periorbital edema secondary to imatinib mesylate
por: McClelland, Collin M, et al.
Publicado: (2010)

Cutaneous adverse effects of imatinib mesylate
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2015)

HOXA4 Gene Promoter Hypermethylation as an Epigenetic Mechanism Mediating Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients
por: Elias, Marjanu Hikmah, et al.
Publicado: (2013)

Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study
por: Matti, Bassam Francis, et al.
Publicado: (2013)

Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia
por: Chen, Yan, et al.
Publicado: (2020)

Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response
por: Ferreira, Amanda Pifano Soares, et al.
Publicado: (2023)

Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose
por: Hislop, Jennifer, et al.
Publicado: (2011)

Chronic myeloid leukemia: an overview of the determinants of effectiveness and therapeutic response in the first decade of treatment with imatinib mesylate in a Brazilian hospital
por: Cid, Danielle Maria Camelo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hihge6k9v6uf1i771uocf6dssd